Long-Term Efficacy and Safety Results from the Phase 3 ERASURE and FIXTURE Trials of secukinumab in Psoriasis

A 4-year extension study of the Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE) and Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE) trials has demonstrated long-term effectiveness of secukinumab (Cosentyx) treatment for patients with moderate-to-severe plaque psoriasis. Read more at the British Journal of Dermatology here:

Reference: Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: Results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198-207.